Celyad Oncology SA
Wed, July 7, 2021, 10:01 PM·3 min read
CLYYF
0.00%
CYAD
-5.48%
MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Chief Scientific Officer, Dr. David Gilham, will participate in a panel discussion titled “Cell Therapies in the Next Decade” to be held on Wednesday, July 14th, at 08:55 a.m. EST at the William Blair Biotech Focus Conference 2021 taking place virtually from July 14-15, 2021. The management team will participate in one-on-one investor meetings throughout the conference as well.
A live audio webcast of the discussion can be accessed through the Events section of the Company’s website.